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To design a releasable PEGylated TNF- (rPEG-TNF-), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into 
conventional PEG-modified TNF- (PEG-TNF-), facilitating its clinical use for anti-tumor therapy. Comparative pharmaco-
kinetic and pharmacodynamic studies showed that the half-lives of both PEGylated forms of TNF-α were ~60-fold greater than 
that of unmodified TNF-. In addition, the in vitro bioactivity of rPEG-TNF- was greater than that of PEG-TNF- with the 
same degree of PEG modification. Release of TNF- from rPEG-TNF- in vitro was dependent on the presence of cathepsin 
B and was inhibited by a cathepsin B inhibitor. Despite the potent cytotoxicity of unmodified TNF- against normal cells, its 
PEGylated forms at higher TNF- concentrations showed low cytotoxic activity against these cells. In contrast, both forms of 
PEGylated TNF- showed potent cytotoxic activity against the B16 and L929 cell lines, with rPEG-TNF- being 5- and 9- 
fold more potent, respectively, than PEG-TNF-. Moreover, rPEG-TNF- was a more potent in vivo antitumor agent than 
PEG-TNF-. 
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TNF-, a cytokine secreted by activated macrophages, has 
potent and specific activity against tumor cells, and has 
been assessed as a novel anti-tumor agent [1,2]. Because of 
its very low in vivo stability and pleiotropic activity, TNF- 
requires continuous infusion or frequent administration at 
high doses to show anti-tumor effects. This, however, re-
sults in the augmentation of its side effects, including fever, 
hypotension, and endotoxin-like shock. When TNF- is used 
clinically systemically, its dose must be limited to 1/5–1/25 
of the dose required to show anti-tumor activities [3].  
To overcome these shortcomings, several strategies have 
been investigated, including new macromolecular carrier 
systems. One of such strategies is PEGylation with a perma-
nent linkage, resulting in an effective drug delivery platform 
[4]. Conjugation of cytokines such as TNF- with PEG has 
been shown to improve their in vivo stability and their ther-
apeutic effects [5–7]. However, the target molecules conju-
gate randomly with PEG, and several active cysteine resi-
dues are unavoidably modified, reducing the biological ac-
tivity of these polypeptides. For example, randomly mono-     
PEGylated interferon alpha 2a (IFN-2a), in which IFN-2a 
conjugated with a 40 kD branched PEG, has only about 7% 
of the bioactivity of unmodified IFN-2a [8]. Recently, 
some PEGylation technologies involving rational design, 
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such as site-specific linkage, have been demonstrated, using 
protein engineering and improved chemical linkages [9,10]. 
The site-specific linkages of PEG may enhance the retention 
of bioactivity, as well as reducing the heterogeneity of the 
PEGylated protein.  
The in vivo bioactivity of protein PEGylated with a per-
manent linkage depends on the slow release of the parent 
drug from the bioconjugate. A new approach to PEGylation, 
in which the release of active drug is controlled, called re-
leasable PEGylation (rPEGylation) [11], employs chemi-
cally designed linkers that are sensitive to proteases specific 
in tumor tissue, allows the release of active drug in tumor 
tissue. Thus rPEGylated compounds are actually prodrugs, 
biologically inactive in the circulation but active at their site 
of action. 
Cathepsin B is a ubiquitous cysteine protease with prop-
erties conserved in multiple species [12]. It is never found 
extracellularly except in pathological conditions such as 
tumors or in areas of tissue destruction such as in rheuma-
toid arthritis [13]. The general substrates of cathepsin B and 
L include dipeptide and tetrapeptide [14]. Tetrapeptide such 
as Gly-Phe-Leu-Gly and Ala-Leu-Ala-Leu were regarded as 
having distinct disadvantages, because of their relatively 
slow drug release and hydrophobic nature, which could 
cause these tetrapeptides to precipitate or aggregate [15–17]. 
Consequently, a dipeptide linker sensitive to cathepsin B 
such as the Val-Cit moiety has been widely utilized in re-
leasable conjugates [18–20]. Those conjugates are highly 
stable in plasma and efficiently release drugs in tumor tis-
sues. 
We have described the synthesis of a releasable 
PEGylated-TNF-, using the Val-Cit moiety to conjugate 
PEG and TNF-. This compound showed enhanced stabil-
ity in human and mouse plasma and sensitivity to cathepsin 
B and rat liver lysosomes. Moreover, the conjugate showed 
potent anticancer activity against Meth-A solid tumors and 
was toxic in vitro to L929 cells [21]. Further studies are 
necessary to determine the anticancer activity of this conju-
gate. We have assessed the sensitivity to cathepsin B of the 
Val-Cit linker containing a p-aminobenzylcarbonyl (PABC) 
spacer (Figure 1), the pharmacokinetics (PK) and pharma-
codynamics (PD) of this compound, its in vitro cytotoxicity 
various normal and cancer cell lines, and its activity again 
S-180 solid tumors. We also compared the activities of 
rPEG-TNF- with those of conventional PEGylated-TNF-α 
(PEG-TNF-) and unconjugated TNF-. These results may 
provide fundamental information for designing more potent 
bioactive protein derivatives against tumors and various 
cardiovascular diseases, and for developing better drug de-
livery systems to further enhance the therapeutic activity 
and safety of conjugated bioactive proteins.  
1  Materials and methods  
1.1  Materials 
Recombinant human TNF- (17000 kD, 1×107 IU mg1 in 
0.2 mol L1 phosphate buffer, pH 7.2) was obtained from 
Biosynthesis Biotechnology Co., Ltd (Beijing, China). The 
40 kD branched N-hydroxylsuccinimide functionalized 
polyethylene glycol (Y-NHS-40k, Polydispersity, 1.05) and 
40 kD branched N-hydroxylsuccinimide functionalized 
PEG-valine-citrulline containing a p-aminobenzylcarbonyl 
spacer (Y-40k-Val-Cit-PABC-NHS, Polydispersity, 1.05) 
were obtained from Jenkem Technology Co., Ltd. (Beijing, 
China). Cathepsin B from human liver (2759 U mg1) was 
purchased from Sigma Corporation. Vascular endothelial 
cells (VEC), melanoma cells (B16) and fibrosarcoma cells 
(L929) were grown in RPMI 1640 medium (Life Technolo-
gies, Gaithersburg, MD) supplemented with 10% fetal bo-
vine serum. Fluorescein isothiocyanate (FITC) was obtained  
 
 
Figure 1  PEG conjugate and cathepsin B reaction products. Enzyme-mediated hydrolysis of the protease-sensitive Val-Cit dipeptide linker followed by 
PABC generates free TNF-.  
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from Biosea Biotechnology Co., Ltd. (Beijing, China) and 
cell counting kits-8 (CCK-8) were from Dojindo Laborato-
ries (Kumamoto, Japan). Other reagents and solvents used 
were of analytical grade. Animal care and handling were 
approved by the Institutional Authority for Laboratory An-
imal Care. 
1.2  Preparation and characterization of TNF- conju-
gates 
The method of preparation of TNF- conjugates has been 
describe [21]. Synthesized rPEG-TNF- and PEG-TNF- 
conjugates were each purified and separated into three frac-
tions of various molecular weights by gel filtration chroma-
tography (GFC) using a Sephacryl S-200HR column on a 
fast protein liquid chromatography system eluted with 0.1 
mol L1 phosphate buffer, pH 7.0. The molecular sizes of 
the PEG-TNF- and rPEG-TNF- conjugates were esti-
mated by GFC analysis, and the degree of PEG-attachment 
to TNF- was assayed by the fluorescamine method [22]. 
The specific in vitro bioactivity of the PEG-TNF- and 
rPEG-TNF- conjugates was measured using L-M cytotox-
icity assay as described [23]. 
1.3  Pharmacokinetics studies 
The pharmacokinetic profiles of TNF- and TNF- conju-
gates in the blood were measured as described [24]. Briefly, 
native TNF-, PEG-TNF-, and rPEG-TNF- were radio-
labeled with 125I by the lactoperoxidase method, with each 
having a specific activity of 4.50 mCi mg1 protein. The 
biological activities of 125I radiolabeled TNF- and its de-
rivatives were indistinguishable from those of nonradio-
labeled TNF- and its derivatives (data not shown). Their 
pharmacokinetic profiles in the blood after intravenous (i.v.) 
injection into normal male BALB/c mice (5 weeks of age) 
were assessed at a dose of 31.6 ng of protein/mouse. Blood 
was collected from the tail vein at various time points, and 
radioactivity was measured in each sample. 
1.4  In vitro evaluation of drug release 
Lysosomes were collected from liver homogenates by cen-
trifugation using the metrizamide discontinuous gradient 
method with slight modifications [21]. All drug release 
studies were performed at 37°C. The concentration of each 
conjugate was 20 g mL1 (17 g TNF-). TNF- and its 
conjugates were labeled with FITC (data not shown). The 
stability of the TNF- conjugates to hydrolysis by rat liver 
lysosomes, papain and cathepsin B was determined by in-
cubating these TNF- conjugates in 50 mmol L1 sodium 
acetate (pH 5.0), 2 mmol L1 dithiothreitol (DTT), and 25% 
(v/v) glycerol at 37°C for 15 min, followed by the addition 
of 20% (v/v) glycerol. The final concentration of lysosome 
was 1 mg mL1 and the final concentrations of papain and 
cathepsin B were 8 mol L1 each. The effects of pH on 
drug release were evaluated by incubating the TNF- con-
jugates in 40 mmol L1 acetate or phosphate buffer at pH 
ranging from 3 to 7. The effects of the enzyme inhibitors 
aprotinin, bestatin, pepstatin, phosphoramidon, E-64, 
Z-Phe-Phe-CHN2, and CA-074 were determined by adding 
each to the conjugate-lysosome mixtures till a final concen-
tration of 10 mol L1. During the process, 100 L aliquots 
were periodically withdrawn. All the samples were lyophi-
lized immediately by adding 1 mL chloroform, vortexing 
for 10 min, and centrifuged at 5000×g for 5 min. The upper 
layer in each tube was collected, and the chloroform was 
removed by lyophilization. The extracted PEG mixture was 
dissolved in 1 mL phosphate buffered saline (PBS) and an-
alyzed by fluorescence spectrophotometry (ex=492 nm, 
em=519 nm). The results were expressed as concentrations 
of TNF-. 
1.5  In vitro cytotoxicity 
Cytotoxicity under starved conditions, was assessed using 
the CCK-8 assay, which is based on the conversion of a wa-
ter-soluble tetrazolium salt, 2-(2-methoxy-4-nitrophenyl)- 
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,  
monosodium salt (WST-8), to a water-soluble formazan dye 
upon reduction by dehydrogenases in the presence of an 
electron carrier [25]. Normal VECs and the tumor cell lines 
B16 and L929 were grown in 96-well plates for 48 h and 
treated with TNF-, PEG-TNF-, or rPEG-TNF- over a 
range of concentrations, with the volume in each well ad-
justed to 200 L by adding culture medium. Following in-
cubation for 24 h, the cells were washed, and cell viability 
was assessed using a CCK-8 assay (Dojindo, Kumamoto, 
Japan). CCK-8 solution (10 L) was added to each well, 
followed by incubation for 2 h at 37°C. The absorbance at 
450 nm was determined using a multiplate reader (Lambda 
Bio-20; Beckman). Cell viability was expressed relative to 
that of control (untreated) cells, and cytotoxicity (C %) was 
calculated using the equation C=(AB)/A×100%, where A is 
the absorption in a control well and, B is the absorption in a 
test well.  
1.6  Screening and evaluation of in vivo anti-tumor ef-
fects 
The in vivo anti-tumor effects of native and conjugated 
TNF- were assessed in mice bearing S-180 solid tumors. 
S-l80 cells were implanted intradermally (4×105 cells/site) 
in male C57BL/6 mice. The mice were assigned to three 
groups of six mice each, and seven days later (tumor size, 
7–8 mm in diameter), each mouse received an intravenous 
injection of native TNF-, PEG-TNF-, or rPEG-TNF-. 
The antitumor potency of TNF-, PEG-TNF- and rPEG-     
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TNF- was evaluated by measuring tumor volume, tumor 
hemorrhagic necrosis scores, and survival time. Tumor 
volume [26] and tumor hemorrhagic necrosis scores [27] 
were determined as described. Sudden death was defined as 
death occurring within 24 h after injection of TNF-, PEG-      
TNF-, or rPEG-TNF-. Complete regression was defined 
as tumors that no longer regrew after more than 150 d. The 
side effects of TNF-, PEG-TNF- and rPEG-TNF- were 
assessed by measuring changes in body weight over a 
25-day period.  
1.7  Statistical analysis 
All data are shown as mean±SD, unless otherwise men-
tioned. Groups were compared using Student’s unpaired 
t-test and one-way analysis of variance.  
2  Results and discussion 
PEGylation is defined as the modification of a protein, pep-
tide or non-peptide molecule by linking of one or more PEG 
chains. These chains are non-toxic, non-immunogenic, 
non-antigenic, highly soluble in water and FDA approved. 
PEGylated drugs have several advantages, including a pro-
longed in vivo half-life, decreased degradation by metabolic 
enzymes and reduced or absent protein immunogenicity. 
PEGylation now plays an important role in drug delivery, 
enhancing the therapeutic potentials of peptides and pro-
teins. However, random conjugation of a polypeptide with 
PEG results in the unavoidable modification of some active 
cysteine residues, reducing the biological activity of these 
drugs. To overcome these limitations, we designed a novel 
rPEG-TNF-, with a cleavable Val-Cit moiety. To assess its 
therapeutic effects, we compared the activities of rPEG-    
TNF-, PEG-TNF- and native TNF-. 
2.1  Preparation and characterization of TNF- conju-
gates 
Recombinant human TNF- was chemically conjugated  
with activated PEG or PEG-Val-Cit containing a PABC 
spacer (average Mw 40000; Mw/average Mw, 1.05) via 
amide bonds between the amino groups of TNF-α and the 
N-hydroxysuccinimide groups of PEG at the end of the 
main chain. PEG attachment to TNF- increased over time 
(data not shown). The resulting PEGylated TNF- conju-
gates were purified from native TNF- and separated into 
three fractions of various molecular sizes by gel filtration-      
high performance liquid chromatography (protein standard). 
Table 1 shows the average Mw, PK, and PD of PEG-TNF- 
and rPEG-TNF-. The dipeptide Val-Cit linker did not alter 
the PK of rPEG-TNF-. The in vivo half-life (t1/2) of 
rPEG-TNF- was 60- to 110-fold higher than that of native 
TNF-, depending on the degree of PEG modification. The 
activities of PEG-TNF-, decreased as the molecular 
weight and degree of PEG modification increased, with the 
in vitro bioactivities of Fractions 2 and 3 being less than 
10% that of native TNF-. These changes in PK and PD 
profiles were similar to those previously reported for PEG 
of TNF-, and suggest that PEG chains sterically inhibit 
PEF-TNF- binding to TNF receptors. Insertion of the di-
peptide Val-Cit into PEGylated TNF- resulted in a mark-
edly improved PD profile. Although changes in rPEG-     
TNF- activity were similar to those of PEG-TNF-, with 
activity associated with increased molecular weight and de-
gree of PEG modification, the bioactivity of rPEG-TNF- 
was noticeably higher than that of PEG-TNF- with the 
same degree of PEG modification. The bioactivity of rPEG-     
TNF- Fraction 1 (Mw 58000) was 77.2% relative to that of 
native TNF-, whereas the bioactivity of PEG-TNF- Frac-
tion 1 (Mw 58700), with the same degree of modification as 
rPEG-TNF- Fraction 1, was only 18.4%. These findings 
suggest that the dipeptide residue in rPEG-TNF- plays an 
important role in increasing the bioactivity of rPEG-TNF-. 
All further experiments, except for those indicated, used 
Fraction 1 of rPEG-TNF-. 
The Val-Cit moiety of rPEG-TNF- is a substrate of ca-
thepsin B. When administrated in vivo, rPEG-TNF- was 
cleaved by cathepsin B, releasing-TNF-.  
Table 1  Comparative pharmacokinetic (PK) and pharmacodynamic (PD) parameters of rPEG-TNF-, PEG-TNF- and native TNF- (n=6 mice each) 





b) Fold differencec) In vitro activity retained (%)d) 
rPEG-TNF- 
1 58000 18.86±2.33**# ↑×60.8  77.2±6.97*## 
2 101000 21.22±2.34** ↑×68.5  48.6±5.71**# 
3 138000 34.09±3.25** ↑×110  28.9±4.22**# 
PEG-TNF- 
1 58700 25.10±1.23** ↑×81  18.4±1.73** 
2 99000 27.23±1.76** ↑×87.8  9.1±0.12** 
3 137000 35.74±1.07** ↑×115.3  6.8±0.28** 
Native TNF-  17000 0.31±0.2 ×1  100.0 
a) Molecular size determined by GFC (protein standard). b) Half time in plasma in vivo after intravenous administration to mice the three TNF- formu-
lations. c) Compared with native TNF-. d) The specific activities of native TNF-, PEG-TNF- and rPEG-TNF- were measured by growth inhibition 
L-M cytotoxic assay. (*P<0.05; **P<0.01 vs. native TNF-; #P<0.05 vs. PEG-TNF- with the same degree of modification). rPEG-TNF-, releasable 
PEGylated-TNF-; PEG-TNF-, PEGylated-TNF-. 
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2.2  In vitro evaluation of drug release 
To confirm whether TNF- can be released by rPEG-TNF-, 
we tested the enzyme and pH specificity of the linker. After 
incubation for 24 h, we found that these TNF- conjugates 
were resistant to rat liver lysosomes and pure enzymes, alt-
hough they were less resistant to rat liver lysosomes and 
cathepsin B than to papain (Figure 2A). Each enzyme has 
an optimal pH, at which the enzymatic activity is maximal. 
To examine the optimal pH for drug release, rPEG-TNF- 
was incubated with rat liver lysosomes or pure enzymes in 
buffers of pH ranging from neutral (pH 7) to acidic (pH 3) 
for 24 h. We found that the optimal pH for TNF- release 
was approximately pH 4, identical to that of cathepsin B, 
suggesting a crucial role for this enzyme in drug release. To 
confirm these results, we investigated the effects of pro-
teinase inhibitors on TNF- release. We found that inhibi-
tors of amino-(bestatin), aspartyl-(pepstatin), and metallo-        
(phosphoramidon) proteinases were all ineffective at con-
centrations of 10 mol L1 (Figure 2B). However, E-64, a 
general inhibitor of cysteine proteases, completely inhibited 
TNF- release from rPEG-TNF-. The serine proteinase  
 
 
Figure 2  Effects of various enzymes at different pH (A) and enzyme 
inhibitors (B) on TNF- release after 24 h incubation of PEG-TNF- at 
37°C. TNF- release was expressed as a percentage relative to that of 
native TNF-. FITC-labeled TNF- conjugates, rat liver lysosome, and 
inhibitor concentrations were approximately 20 g mL1, 0.5 mg mL1 of 
protein, and 10 mol L1, respectively. Conditions: 40 mmol L1 acetate 
buffer (pH 4.0), 1 mmol L1 EDTA, 5 mmol L1 reduced glutathione, 0.1% 
Triton X-100, 37°C (n=4). 
inhibitor aprotinin partially inhibited this release, probably 
due to its high concentration. These findings confirm that 
cysteine proteases are highly responsible for the cleavage of 
the Val-Cit linker. Cathepsins B and L are lysosomal cyste-
ine proteases, which are involved in maintaining normal 
cellular metabolism [28]. To determine their contribution to 
rPEG-TNF- cleavage, similar experiments were performed 
using specific inhibitors of cathepsin B, (CA-074) [29], and 
cathepsin L, (Z-Phe-Phe-CHN2) [30]. We found that both 
inhibitors suppressed TNF- release, even at 10 mol L1 
(Figure 2B), confirming that lysosomal cathepsin B is re-
sponsible for the in vivo cleavage of rPEG-TNF-. 
2.3  In vitro cytotoxicity 
We evaluated the cytotoxicity of TNF- and its conjugates 
using one normal cell line, VEC, and two cancer cell lines, 
B16 and L929. Both TNF-α conjugates showed slight cyto-
toxic activity against VECs, with 5000 U mL1, of each 
having less than 20% cytotoxicity (Figure 3). Moreover, the 
cytotoxicities of PEG-TNF- and rPEG-TNF- did not differ 
significantly. At higher concentrations (>5000 U mL1); 
however, these conjugates exhibited stronger cytotoxicity, 
up to 60%, against VECs (Figure 3A). At the same doses, 
both forms of PEGylated TNF- were more cytotoxic to 
B16 and L929 cells, a difference likely due to the presence 
of cathepsin B in tumor tissue [16]. Moreover, the cytotoxi-
city of rPEG-TNF- toward B16 (IC50 (5368.06±46.28) IU 
mL1; Figure 3B) and L929 (IC50 (3263.18±32.27) IU mL1; 
Figure 3C) cells, was about 5 and 9-fold higher than that of 
PEG-TNF- against B16 (IC50 (30233.06±204.22) IU mL1) 
and L929 (IC50 (27356.81±274.08) IU mL
1) cells, respec-
tively. Additional modification of the dipeptide linkers or of 
PEGylation may enhance the in vitro cytotoxicity of rPEG-    
TNF-. We also found that the cytotoxicity of rPEG-TNF- 
was dose- and time-dependent. The low cytotoxicity of 
PEG-TNF- may be due to the incomplete modification of 
PEG. PEGylation of proteins is accompanied by a signifi-
cant loss of their activities.   
2.4  Screening and evaluation of in vivo anti-tumor ef-
fects 
We also compared the anti-tumor effects of single intrave-
nous injections of rPEG-TNF-, PEG-TNF- and native 
TNF- into S-180 solid tumors (Figure 4A). Although na-
tive TNF- inhibited tumor growth in a dose-dependent 
manner, all mice receiving 10000 IU native TNF- experi-
enced side effects, including a transient decrease in body 
weight. Consequently, 10000 IU of native TNF- was con-
sidered the maximum applicable dose. We found that 
PEG-TNF- at doses of 200 and 1000 IU/mouse slightly 
inhibited S-180 tumor growth, whereas 50 IU rPEG-TNF-  
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Figure 3  In vitro cytotoxicity of TNF- and TNF- conjugates on VEC 
(A), B16 (B), and L929 (C) cells. Cytotoxicity was measured using CCK-8 
assays after incubation for 48 h (n=6). rPEG-TNF-, releasable PEGylat-
ed-TNF-; PEG-TNF-, PEGylated-TNF-. 
and 1000 IU PEG-TNF- showed anti-tumor effects com-
parable to those of native 10000 IU TNF- (Figure 4B). 
Both TNF- conjugates were well tolerated, with none of 
the mice showing body weight reductions. However, the 
anti-tumor effects of rPEG-TNF- were superior to those of 
PEG-TNF-, suggesting that the Val-Cit moiety contributed 
to the improvement in PD. PEG shielding of the proteolytic 
cleavage sites of TNF- and the reduction in renal clearance 
due to increased molecular size increased the circulation 
time and plasma stability of both PEG-TNF- and rPEG-    
TNF-, as shown in our PK experiments. In addition, the 
accumulation and retention of macromolecules are greater 
in tumor than in normal tissues, a phenomenon called the 
“enhanced permeability and retention (EPR)” effect [31]. 
rPEG-TNF- was cleaved by cathepsin B, which is abun-
dant in tumor tissues, resulting in the efficient release of 
TNF- and ultimately, a higher anti-tumor potency than  
 
Figure 4  Anti-tumor effects of native TNF- and TNF- conjugates on 
S-180 solid tumors in mice. Eleven days after tumor inoculation, 6 mice 
each were intravenously injected with native TNF- (A) or TNF- conju-
gates (B) twice weekly for two weeks (arrows). Each value represents the 
mean±SD. *, P<0.01 compared with saline control. rPEG-TNF-, releasa-
ble PEGylated-TNF-; PEG-TNF-, PEGylated-TNF-.  
 
observed for PEG-TNF-. 
To confirm that the Val-Cit moiety is a polymeric modi-
fier and that rPEG-TNF- is a systemic anti-tumor agent, 
we compared the anti-tumor potencies of rPEG-TNF-, 
PEG-TNF- and native TNF- against S-180 solid tumors. 
Following a single intravenous administration, native TNF- 
dose-dependently induced tumor hemorrhagic necrosis in 
S-180 solid tumors (Figure 5) and slightly inhibited tumor 
growth (data not shown). However, four of the six mice that 
received 10000 U native TNF- died within 24 h after in-
jection, and the remaining mice showed toxic side effects 
such as piloerection, tissue inflammation, and/or decreased 
body weight. In comparison, the anti-tumor effects of 
rPEG-TNF- were markedly increased compared with na-
tive TNF-, with 50 IU of rPEG-TNF-, causing marked 
hemorrhagic necrosis, similar to that observed with 10000 
IU of native TNF-. In contrast to the latter, none of the 
mice administered rPEG-TNF- experienced sudden death 
or toxic side effects. We found that the anti-tumor effects of 
1000 IU PEG-TNF- were equivalent to those of 50 IU 
rPEG-TNF-. These results indicated that rPEG-TNF- 
was approximately 200-fold more potent than native TNF-α 
and 20-fold more potent PEG-TNF-. 
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Figure 5  Tumor necrotic effects of native TNF-, rPEG-TNF-, and PEG-TNF- on S-180 solid tumors. Mice were assigned into groups of six. Necrosis 
scores of 3, 2, 1, and 0 indicated that 50%, 25%–50% necrotic, <25%, and 0%, respectively, of the tumor was. Each value represents the mean±SD. *, 
P<0.01 compared with saline control. ND, not detected. rPEG-TNF-, releasable PEGylated-TNF-; PEG-TNF-, PEGylated-TNF-.  
3  Conclusion 
We found that PEGylation of TNF- using a Val-Cit linker 
containing a PABC spacer yielded a more potent product 
than conventional PEGylation. Although both types of 
PEGylated TNF- had similar structure, rPEG-TNF- 
showed more potent cytotoxic and anti-tumor activities, 
indicating that the conjugation of TNF- with PEG and a 
Val-Cit moiety selectively increased its bioactivity in vitro 
and in vivo, rPEG-TNF- may therefore be a more potent 
anti-tumor therapeutic agent than PEG-TNF-. 
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